The Filtrate: Joel Topf Swapnil Hiremath Jordy Cohen AC Gomez With Special Guest: Tim Anderson @TimAndersonMD Editor: Priya Yenebere Show Notes Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older Adults NephJC Summary | PubMed | JAMA Internal Medicine The Jordy AC collab: An Interactive Ambulatory Nephrology Curriculum for Internal Medicine Interns: Design, Implementation, and Participant Feedback (PubMed) Clinical Outcomes After Intensifying Antihypertensive Medication Regimens Among Older Adults at Hospital Discharge (PubMed) Trends in Blood Pressure Trea ..read more

How Medicine Works, and When It Doesn’t Amazon The Filtrate: Joel Topf Josh Waitzman Jennie Lin With Special Guest: Jade Teakell Perry Wilson Editor: Joel Topf Show Notes Understanding Medical Research: Your Facebook Friend is Wrong. Coursera Illusory truth effect (Wikipedia) Number needed to treat (Wikipedia) NNT at MedPage Today: NNT on NephJC Deaths of Despair: Suicide (CDC 2001-2021) Drug Overdose (CDC 2001-2021) Steve Jobs delayed therapy for his treatable pancreatic cancer (ABC News) Residents are unionizing at Mass General Brigham. Here's what you need to know (WBUR) Pi and bouncing bri ..read more

The Filtrate: Joel Topf Nayan Aurora Sophia Ambruso With Special Guest: Michael Collins Editor: Nayan Aurora Show Notes: Twitter is now X (NYT) Michael Collins (the astronaut, not the real one) PlasmaLyte by Baxter NephJC BEST Fluids summary Early Goal Directed Therapy for Sepsis NEJM manuscript which changed practice patterns and welcomed in an era of massive fluid resuscitation. PLUS Trial NEJM SPLIT Trial JAMA BaSICS NephJC Summary SALTED and SMART NephJC Summary Adaptive minimization wikipedia BEST Fluids statistical plan BEST Fluids in CLinicalTrials.gov Delayed Graft Function review in ..read more

The Filtrate: Joel Topf Swapnil Hiremath Sophia Ambruso AC Gomez With Special Guest: Amit Garg (@AmitXGarg) Nephrologist at Western University, London, and lead PI of the EnAKT LKD trial.  Susan Q. McKenzie (LinkedIn) Co-Founder & Chair, Transplant Ambassador Program. President of the Kidney Patient and Donor Alliance of Canada. Editor: Joel Topf Show Notes: Late Braking and High Impact Clinical Trial press release JAMA Internal Medicine MyTEMP trial Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial (PubMed ..read more

The Filtrate: Joel Topf Jennie Lin Josh Waitzman With Special Guest: AC Gomez MedPeds nephrology fellow at Mass General/Brigham and Boston Children’s | Twitter Gentian Hall Assistant Professor of Medicine Duke Department of Medicine Editor: Sophia Ambruso Show Notes: APOL1 review by the OG Scientists APOL1 Nephropathy: From Genetics to Clinical Applications MYH9 and APOL1 connection: The population genetics of chronic kidney disease: insights from the MYH9–APOL1 locus Martin Pollack Lab Vertex Lab Worldwide Frequencies of APOL1 Renal Risk Variants (NEJM) Kidney Disease-Associated APOL1 Variant ..read more

Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients. The Filtrate: Joel Topf Nayan Arora Swapnil Hiremath Pirya Yenebere With Special Guest: Nav Tangri nephrologist and epidemiology at the University of Manitoba Editor: Nayan Arora Show Notes: Arsenal FC The London study that kicked it all off! de Brito-Ashurst, I., Varagunam, M., Raftery, M. J., & Yaqoob, M. M. (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status. Journal of the American Society of Nephrology: JASN, 20(9), 2075–2084. The multi ..read more

The Filtrate: Joel Topf Nayan Arora Swapnil Hiremath Pirya Yenebere With Special Guest: Nav Tangri nephrologist and epidemiology at the University of Manitoba Editor: Nayan Arora Show Notes: Arsenal FC The London study that kicked it all off! de Brito-Ashurst, I., Varagunam, M., Raftery, M. J., & Yaqoob, M. M. (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status. Journal of the American Society of Nephrology: JASN, 20(9), 2075–2084. The multi center (but unblinded) UBI Study with mortality benefit! Di Iorio, B. R., Bellasi, A., Raphael, K. L., Santo ..read more

The Filtrate: Joel Topf Nayan Arora Sophia Ambruso With Special Guest: Boback Ziaeian @boback Assistant Professor of Medicine David Geffen School of Medicine at UCLA. His Google Schoolar page is better than yours. And returning for her fourth time (why do we keep inviting her back?) Sadiya Khan @heartDocSadiya Assistant Professor of Medicine (Cardiology) and Preventative Medicine at Northwestern Feinberg School of Medicine. Link Editor: Priya Yenebere Show Notes: Diuretic Therapy review by. Craig Brater NEJM The manuscript in JAMA | NephJC Metoprolol vs Carvedilol: Comparison of carvedilol a ..read more

The Filtrate: Joel Topf Swapnil Hiremath Josh Waitzman Nayan Arora Sophia Ambruso With Special Guest: Megan Prochaska Assistant professor of medicine at University of Chicago John Asplin Medical Director Consultant LithoLink (Twitter) Editor: Joel Topf Show Notes: The LithoLink website Stone Camp tweet Prevention of Repeated Episodes of Kidney Stones in Adults: A Clinical Practice Guideline From the American College of Physicians (link) NOSTONE in the NEJM and NephJC Fred Coe Google Scholar | YouTube | Blog Hypercalcuria. Curhan et al. 24-h uric acid excretion and the risk of kidney stones ..read more

The Filtrate: Joel Topf Swapnil Hiremath Josh Waitzman Jordy Cohen With Special Guest: Areef ishani lead author and Chief of Medicine VA Minneapolis Editor: Nayan Arora Show Notes: MRFIT switches diuretics and finds better outcomes. Swapnil shows how many studies he is familiar with by spewing out a string of them. Chlorthalidone wins: ALLHAT, MRFIT, SPRINT, HYVET, CLICK (not mentioned by Swap but by Jordy later) HCTZ loses: HOPE3, ACCOMPLISH Diuretic half-lifes NEJM review Edarbyclor: Azilsartan and Chlorthalidone $240/month as per GoodRx Nice mention of late study originator Frank Lederle ..read more